Vanguard Fiduciary Trust
SLDB icon

Vanguard Fiduciary Trust’s Solid Biosciences SLDB Stock Holding History

Vanguard Fiduciary Trust’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.94M Buy
494,730
+168,751
+52% +$1.28M ﹤0.01% 2185
2026
Q1 		$2.35M Buy
+325,979
New +$2.09M ﹤0.01% 2480

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust's SLDB Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Solid Biosciences (SLDB) stake by 52% in Q2 2026, buying an estimated $1.28M and bringing the position to 494,730 shares worth $4.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2185.

Vanguard Fiduciary Trust first reported a position in SLDB in Q1 2026 and has held it in 2 quarters since. 156 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Vanguard Fiduciary Trust held 494,730 shares of Solid Biosciences worth $4.94M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 168,751 Solid Biosciences shares in Q2 2026, an estimated $1.28M.
  • Solid Biosciences made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2185 holding.
  • Vanguard Fiduciary Trust first reported a position in Solid Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 156 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.